Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 5
Submit an article Journal homepage
40
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic lymphocytic leukemia (CLL)

Amen Allah Nasra APHP-Paris Saclay, Service d’Hématologie-Bicêtre, Kremlin-Bicêtre, France;b Faculté de Médecine Paris-Saclay, Université Paris-Saclay, Kremlin-Bicêtre, France;c Inserm UMR-S 1310, Villejuif, FranceView further author information
,
Xavier Fundc Inserm UMR-S 1310, Villejuif, France;d APHP Paris Saclay Service d’Oncohématologie moléculaire et Cytogénétique Hôpital Paul-Brousse, Villejuif, FranceView further author information
,
Sylvain Barreaua APHP-Paris Saclay, Service d’Hématologie-Bicêtre, Kremlin-Bicêtre, France;c Inserm UMR-S 1310, Villejuif, FranceView further author information
,
Christophe Desterkeb Faculté de Médecine Paris-Saclay, Université Paris-Saclay, Kremlin-Bicêtre, France;c Inserm UMR-S 1310, Villejuif, FranceView further author information
,
Claire Boriec Inserm UMR-S 1310, Villejuif, France;d APHP Paris Saclay Service d’Oncohématologie moléculaire et Cytogénétique Hôpital Paul-Brousse, Villejuif, FranceView further author information
,
Noufissa Oudrhiria APHP-Paris Saclay, Service d’Hématologie-Bicêtre, Kremlin-Bicêtre, France;c Inserm UMR-S 1310, Villejuif, France;d APHP Paris Saclay Service d’Oncohématologie moléculaire et Cytogénétique Hôpital Paul-Brousse, Villejuif, FranceView further author information
,
Jamila Faivred APHP Paris Saclay Service d’Oncohématologie moléculaire et Cytogénétique Hôpital Paul-Brousse, Villejuif, FranceView further author information
,
A. Bennaceur-Griscellia APHP-Paris Saclay, Service d’Hématologie-Bicêtre, Kremlin-Bicêtre, France;b Faculté de Médecine Paris-Saclay, Université Paris-Saclay, Kremlin-Bicêtre, France;c Inserm UMR-S 1310, Villejuif, France;d APHP Paris Saclay Service d’Oncohématologie moléculaire et Cytogénétique Hôpital Paul-Brousse, Villejuif, France;e Centre for iPSC Therapies (CITHERA) INSERM UMS 45, GenopoleEvry, FranceView further author information
&
A. G. Turhana APHP-Paris Saclay, Service d’Hématologie-Bicêtre, Kremlin-Bicêtre, France;b Faculté de Médecine Paris-Saclay, Université Paris-Saclay, Kremlin-Bicêtre, France;c Inserm UMR-S 1310, Villejuif, France;d APHP Paris Saclay Service d’Oncohématologie moléculaire et Cytogénétique Hôpital Paul-Brousse, Villejuif, France;e Centre for iPSC Therapies (CITHERA) INSERM UMS 45, GenopoleEvry, France;f Department of Hematology, American Hospital of Paris, Neuilly Sur Seine, FranceCorrespondence[email protected]
View further author information
 show all
Pages 692-695 | Received 20 Nov 2023, Accepted 17 Jan 2024, Published online: 31 Jan 2024

References

  • Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941–D947. doi:10.1093/nar/gky1015
  • Ferran N, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016;127(17):2122–2130. doi:10.1182/blood-2015-07-659144
  • Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 Wild-Type chronic lymphocytic leukemia. Blood. 2012;119(12):2854–2862. doi:10.1182/blood-2011-12-395673
  • Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525–530. doi:10.1038/nature15395
  • Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088
  • Yamato A, Soda M, Ueno T, et al. Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-κB-Activating potential. Cancer Sci. 2015;2015;106(9):1137–1142. doi:10.1111/cas.12726
  • Fazi C, Scarfò L, Pecciarini L, et al. General population low-count CLL-like MBL persists over time without ­clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood. 2011;118(25):6618–6625. doi:10.1182/blood-2011-05-357251
  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
  • Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015;126(4):454–462. doi:10.1182/blood-2015-02-585059
  • Defrancesco I, Zibellini S, Boveri E, et al. Targeted next-generation sequencing reveals molecular heterogeneity in non- chronic lymphocytic leukemia clonal B-cell lymphocytosis. Hematol Oncol. 2020;38(5):689–697. doi:10.1002/hon.2784
  • Mansouri L, Thorvaldsdottir B, Sutton LA et al: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia. 2023 Feb;37(2):504. doi: 10.1038/s41375-023-01813-3. Erratum for: Leukemia. 2023 Feb;37(2):339-347. PMID: 36635392; PMCID: PMC9898025.
  • Maher N, Mouhssine S, Matti BF, et al. Treatment refractoriness in chronic lymphocytic leukemia: old and new molecular biomarkers. Int J Mol Sci. 2023;24(12):10374. doi:10.3390/ijms241210374PMID: 37373521;
  • Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916. doi:10.1056/NEJM200012283432602
  • Rose-Zerilli MJ, Forster J, Parker H, et al. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Haematologica. 2014;34(7):1760–1774. doi:10.3324/haematol.2013.098574
  • Frazzi R. BIRC3 and BIRC5: multi-faceted inhibitors in cancer. Cell Biosci. 2021;11(1):8. doi:10.1186/s13578-020-00521-0
  • Tausch E, Stilgenbauer S. BIRC3 mutations in chronic lymphocytic leukemia - uncommon and unfavorable. Haematologica. 2020;105(2):255–256. doi:10.3324/haematol.2019.238691
  • Galigalidou C, Zaragoza-Infante L, Iatrou A, et al. Understanding monoclonal B cell lymphocytosis: an interplay of genetic and microenvironmental factors. Front Oncol. 2021;11:769612. doi:10.3389/fonc.2021.769612

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.